Sponsors & Exhibitors

Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries.

For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery*, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

For more information, please visit: www.insulet.com and www.omnipod.com.

At Abbott, we’re dedicated to helping people live more fully, in everything we do. We’re creating the future of healthcare through life-changing technologies and products that make you healthier and stronger, quickly identify when you have a medical need, and treat conditions to help you get back to doing what you love.

With headquarters in north suburban Chicago, we serve people in more than 160 countries with leading medical devices, diagnostics, nutrition products and branded generic medicines. Our 114,000 colleagues are helping millions of people to live better and healthier, every day around the world.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products.
We are focused on making breakthrough technology accessible and approachable for all. Our groundbreaking sensing technology has revolutionized how people monitor glucose and provides physicians with more data to make better informed treatment decisions.

Boehringer Ingelheim has been transforming lives in healthcare since 1885. Our 53,000 employees in 130 markets create value through innovation by infusing long-term, sustainable thinking into our Human Pharma and Animal Health units. We acknowledge the deep and complex ways the lives of humans and animals are interconnected and work on breakthrough therapies and co-create solutions that help millions of people worldwide live longer, healthier lives.

Amgen is a leading global biotechnology company committed to discovering, developing, manufacturing, and delivering innovative human therapeutics. Founded in 1980, Amgen uses advanced science, technology, and human genetic insights to address serious diseases in oncology, cardiovascular disease, inflammation, osteoporosis, and rare conditions. Its medicines reach millions of patients across nearly 100 countries. With a strong research pipeline and reliable biologics manufacturing, Amgen continues to pioneer breakthroughs that improve patient outcomes. Guided by responsible operations and scientific excellence, Amgen remains dedicated to advancing biotechnology and transforming the lives of people facing serious illnesses worldwide.

Dexcom is a US-based multinational med-tech company specializing in diabetes technology management and solutions. Dexcom is well known for pioneering the continuous glucose monitoring industry, with more than 25 years of experience in products and over 65 years of research and development.
Dexcom operates in more than 65 countries across the world, including a presence in the Middle East and Africa.

Our mission is: empowering people to take control of health.

Merck KGaA, Darmstadt, Germany, is a leading global science and technology company with a rich heritage dating back to 1668. Headquartered in Darmstadt, the company operates across three main sectors: Healthcare, Life Science, and Electronics. With approximately 63,000 employees in over 70 countries, Merck KGaA is committed to advancing health and well-being through innovative solutions that harness the power of science and technology.

In its Healthcare sector, Merck KGaA focuses on developing treatments for a variety of diseases, including cancer, autoimmune disorders, neurological conditions, and reproductive health issues. The company is dedicated to improving patient outcomes and enhancing the quality of life for individuals affected by these conditions. Its commitment to sustainability and responsible business practices further underscores its mission to make a positive impact on society.

For more information, visit Merck KGaA Official Website.

With a successful track record spanning over 55 years, Modern Pharmaceutical LLC is one of the UAE's leading distributor and healthcare service providers, delivering end-to-end solutions across the healthcare landscape.

Our commitment is to deliver the best healthcare products and services from around the world into the dynamic and fast-growing UAE healthcare ecosystem.

Our integrated 360° solutions connect every touchpoint of the healthcare journey, from regulatory coverage, market access, medical affairs, marketing and demand creation, and supply chain management to our owned and managed pharmacies and power retail network, and more.

We proudly provide the strongest back-end support & infrastructure systems, machinery, logistics to an expanding network of 146+ hospitals, 2000+ pharmacies, 62+ institutions, 720+ retail outlets, 40+ wholesale partners, and many other platforms to meet the diverse healthcare needs our customers and principals.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious diseases. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com & connect with us on LinkedIn, Facebook, and Instagram.

Pharma World LLC was established in 1977 by Dr. Jumaa Belhoul

Pharma World LLC provides end-to-end healthcare solutions, encompassing the importation, registration, distribution, marketing, and sale of pharmaceutical products, medical devices, disinfectants, skin care and cosmeceutical products, food supplements, and dietary nutrition.

MISSION: To enhance patients’ quality of life by licensing, distributing, and promoting safe, effective, and affordable medicines. This mission supports broader public health objectives by ensuring access to essential treatments while maintaining strict oversight of product safety, regulatory compliance, and ethical standards.

VISION: Focuses on developing markets by leveraging its internal marketing and sales capabilities, with a commitment to advancing public health, medical knowledge, and the delivery of reliable and safe therapies.

Who Are We:

Recordati has been at the forefront of life-enhancing and life-changing medicines for almost 100 years.

With its beginnings in a family run pharmacy in Correggio, Italy in the 1920s, Recordati is now a global pharmaceutical force, listed on the Italian stock exchange, with around 4,580 employees.

We are a group of like-minded, passionate individuals who go to extraordinary lengths for our partners, customers, investors and the people across the globe who we serve.

We develop and commercialize medicines to serve people living with common diseases, as well as those living with some of the rarest, in around 150 countries.

At Recordati, our mantra is simple. We’ve always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege. Whether that is for common diseases or the rarest – we want to give people the opportunity to be the best version of themselves.

This drive will never stop. Together, we will always be reimagining tomorrow – with new ideas, new technologies and new innovations to fight diseases.

Our Purpose:

Unlocking the full potential of life

RECORDATI IN A NUTSHELL

• HQ in Milan, Italy has been listed on the Italian stock exchange since 1984
• Produces and promotes a wide range of products in around 150 countries
• Around 4,580 employes
• Portfolio includes products for both primary and specialty care and treatments for rare diseases
• European partner of leading international pharmaceutical companies
• Markets a number of specialties generated by our research & development hubs
• 2 pharmaceutical chemicals plants
• 7 pharmaceutical manufacturing plants
• 1 packaging and distribution plant handling drugs for rare diseases

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the worlds largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In the Middle East, Roche Diagnostics offers comprehensive expertise through the relevant and appropriate channels in 14 countries: UAE, Saudi Arabia, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon, and Maldives. For more information, please visit www.roche-middleeast.com

Ascensia Diabetes Care is a global company entirely dedicated to improving the health and lives of people with diabetes. Established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings, Ascensia is headquartered in Basel, Switzerland. We have more than 80 years of history helping people manage their diabetes, and our products are sold in over 100 countries worldwide.

We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems. We are committed to adding more innovative and life-changing products to our portfolio.

Biocon Biologics Limited stands as a leading global biopharmaceutical player specializing in biosimilars. With its purpose-driven mission, integrated business model, and diverse portfolio, it strives to make biologic therapies affordable and accessible to patients around the world, particularly in major regulated markets and emerging economies.

Biocon Biologics’ manufacturing sites are equipped with world-class quality systems and are approved by major regulators such as U.S. FDA, EMA, TGA (Australia), ANVISA (Brazil), and NPRA (Malaysia).

After acquiring the global biosimilars business from Viatris, Biocon Biologics became a fully integrated global biosimilars company with enhanced scale and reach.

The company has reached significant revenue milestones and continues to drive global expansion.

• Products are marketed in 100+ countries spanning developed and emerging markets.
• The company impacts millions of patients annually by providing affordable biologic medicines.

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological product.

With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.

Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory,gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.

EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide

For more information, please visit: www.evapharma.com & https://www.evapharma.com/newsroom
follow us on Facebook, LinkedIn & Instagram

Wholly owned by Dubai Investments PJSC (one of leading companies listed in Dubai Financial Market) through it’s subsidiary Dubai Investments Industries LLC

Globalpharma has been well known by its high standard quality of operations, passing all inspections with no quality issues and ZERO recall/withdrawal of any of Globalpharma batches. Due to this trust we are in a manufacturing partnership for anti-infectives for GSK In the region, as well as antihypertensives for regional international corporations.

Since Globalpharma was partially acquired by one of the top leading Multinational companies (Sanofi) for 5 years. This contributed to upgrading our manufacturing process to meet the highest quality standards for global leaders in Pharma industry, which we have continued till this day.

Gulf Med Medicines is a leading health care provider introducing innovative products and services to Health Care professionals through a very ambitious and highly competitive team operating in the middle east countries providing regional business at regional standards by more than 500 employees across its subsidiaries in the UAE , Saudi Arabia , Qatar , Oman , Kuwait, Egypt , Libya and Iraq.

At Julphar, our mission is simple — to provide a better quality of life for the entire family by delivering best in class solutions and real value.

We produce a wide range of medicines, vaccines and consumer healthcare products for conditions ranging from headaches to heart disease.

Our state-of-the-art facilities have comprehensive manufacturing capabilities and meet the highest standards of quality and safety.

Pharmalink is one of the UAE's leading healthcare organizations, boasting over two decades of expertise in supplying premium pharmaceutical and healthcare products nationwide. Our comprehensive portfolio includes life-saving and emergency medicines, medical consumables, and over-the-counter (OTC) solutions designed to meet the needs of all age groups and medical specialties, from pediatrics and beyond.

Our strong partnerships with renowned global manufacturers from Europe, North America, Asia, and key markets worldwide enable us to deliver innovative, high-quality treatments reliably. Pharmalink upholds the highest standards of quality, and service excellence to support healthcare professionals and patients throughout the UAE.

Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world.

The Group's unique governance model ensures its independence while fostering long-term innovation, with 100% of its profits reinvested in the company's development.

As a world leader in cardiometabolism and venous diseases, Servier drives transformative innovation in chronic conditions through a holistic approach, making patient adherence a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology.

Bolstered by its success in oncology, Servier has expanded into neurology. The Group focuses on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine.

Headquartered in France, Servier operates in close to 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved sales revenue of €5.9 billion